Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Oppenheimer

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reissued by stock analysts at Oppenheimer in a research report issued on Thursday.

Several other analysts have also recently issued reports on the stock. BTIG Research raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Monday, September 11th. TheStreet cut shares of Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. Credit Suisse Group reissued an “underperform” rating and set a $8.00 price target (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Royal Bank of Canada set a $11.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research report on Wednesday, November 29th. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 31st. Seven analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and a consensus price target of $19.34.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up $1.54 on Thursday, hitting $17.24. 86,177,930 shares of the stock traded hands, compared to its average volume of 15,888,267. The firm has a market capitalization of $16,784.32, a PE ratio of 3.82 and a beta of 0.55. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $38.31. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

A number of institutional investors have recently made changes to their positions in TEVA. Capital Research Global Investors increased its stake in Teva Pharmaceutical Industries by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. increased its stake in Teva Pharmaceutical Industries by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC increased its stake in Teva Pharmaceutical Industries by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Macquarie Group Ltd. increased its stake in Teva Pharmaceutical Industries by 350.3% in the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after purchasing an additional 3,429,448 shares during the last quarter. Finally, Capital World Investors increased its stake in Teva Pharmaceutical Industries by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after purchasing an additional 3,268,200 shares during the last quarter. Institutional investors own 52.05% of the company’s stock.

WARNING: “Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Oppenheimer” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/14/teva-pharmaceutical-industries-teva-stock-rating-reaffirmed-by-oppenheimer.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply